SOPHiA GENETICS Boosts Revenue 27% on U.S. and BioPharma Growth
Event summary
- SOPHiA GENETICS reported Q2 2026 revenue of $23.3M, up 27% YoY.
- Adjusted EBITDA loss improved by 27% YoY to $8.8M.
- Company signed two companion diagnostic programs with AstraZeneca, its first-ever BioPharma deals.
- U.S. revenue grew 64% YoY, driven by 60% volume growth and new customer wins.
- Raised full-year 2026 revenue guidance to $94M–$96M (prior: $92M–$94M).
The big picture
SOPHiA GENETICS's Q2 2026 results highlight its strategic pivot toward BioPharma partnerships and U.S. market expansion, key growth drivers in the AI-driven precision medicine sector. The company's ability to improve adjusted EBITDA loss while raising revenue guidance underscores its operational discipline amid competitive pressures in genomics and diagnostics.
What we're watching
- BioPharma Expansion
- Whether SOPHiA GENETICS can sustain BioPharma growth momentum into 2027 following its first-ever companion diagnostic deals with AstraZeneca.
- U.S. Market Penetration
- The pace at which the company can convert its 64% YoY U.S. revenue growth into profitable, scalable operations.
- Operational Efficiency
- How targeted cost actions and AI-driven productivity improvements will impact adjusted EBITDA breakeven timeline by year-end 2026.
Related topics